Insulins today and beyond

Lancet

Volumn 358, Issue 9283, 2001, Pages 739-746

  Owens, David R ^a   Zinman, Bernard ^b   Bolli, Geremia B ^c  

^a LLANDOUGH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BIPHASIC INSULIN; DIAZEPAM; DIMER; GLIBENCLAMIDE; GLIPIZIDE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HUMAN INSULIN; IBUPROFEN; INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; INSULIN RECEPTOR; INSULIN ZINC SUSPENSION; INSULIN[B10 ASPARTIC ACID]; ISOPHANE INSULIN; METFORMIN; NEUTRAL PROTAMINE LISPRO; PROINSULIN; UNCLASSIFIED DRUG;

BOLUS INJECTION; BREAST TUMOR; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DISEASE COURSE; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG FORMULATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SYNTHESIS; GLUCOSE BLOOD LEVEL; HORMONE SUBSTITUTION; HUMAN; HYPOGLYCEMIA; INJECTION PAIN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN SYNTHESIS; INSULIN TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; REVIEW; TISSUE SPECIFICITY;

EID: 0035448570     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(01)05842-1     Document Type: Review

References (87)

1. The effect of intensive treatment of diabetes on the development and progressing of long-term complications in insulin-dependent diabetes mellitus
2. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes
3. Insulin analogues
4. Insulin analogues and their potential in the management of diabetes mellitus
5. Insulin analogs with improved pharmacokinetic profiles
6. The physiological replacement of insulin: An elusive goal
7. Insulin management and metabolic control in type1 diabetes mellitus in childhood and adolescence in 18 countries
8. Insulin pharmacokinetics
9. Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency
10. Correlations of reception binding and metabolic and mitogenic potentials of insulin analogues designed for clinical use
11. [Lys(B28), Pro(B29)]-Human Insulin: A rapidly absorbed analogue of human insulin
12. Comparative pharmacokinetics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers
13. Insulin lispro
14. Insulin aspart: A novel rapid-acting human insulin analogue
15. Reduction of postprandial hyperglycaemia and frequency of hypoglycaemia in IDDM patients on insulin-analog treatment
16. Use of insulin aspart, a fast acting insulin analog, as the meal time insulin in the management of patients with type 1 diabetes
17. Exercise-induced hypoglyceamia in IDDM patients treated with a short-acting insulin analog
18. Effects of short-acting insulin analog [Lys(B28), Pro(B29)] on postprandial blood glucose control in IDDM
19. Use of the short-acting insulin analogue lispro in intensive treatment of type 1 diabetes mellitus: Importance of appropriate replacement of basal insulin and time-interval injection-meal
20. A randomized, controlled trial comparing insulin lispro with human soluble insulin in patients with type 1 diabetes on intensified insulin therapy
21. Meta-analysis of the effect of insulin lispro on severe hypoglycaemia patients with type 1 diabetes
22. Hypoglycaemia and insulin analogues: Is there a reduction in the incidence?
23. Improved glycaemic control with insulin aspart - A multicentre randomized double-blind cross-over trial in type 1 diabetes mellitus
24. Insulin aspart versus human insulin in the management of long-term blood glucose control in type 1 diabetes mellitus: A randomised controlled trial
25. Effect of the fast-acting insulin analog lispro on the risk of nocturnal hypoglycaemia during intensified insulin therapy
26. Long term intensive treatment of type 1 diabetes with the short-acting insulin analog Lispro in variable combination with NPH insulin at mealtime
27. Improvement of blood glucose control in type 1 diabetic patients treated with lispro and multiple NPH injections
28. Insulin lispro in CSII: Results of a double-blind cross-over study
29. 1c and blood glucose stability in IDDM patients treated with lispro insulin analog in external pumps
30. Use of insulin lispro in continuous subcutaneous insulin infusion treatment: Results of a multicenter trial
31. Pre-meal insulin analogue insulin lispro vs Humulin R insulin treatment in young diabetics with type 1 diabetes
32. Rapid appearance and onset of action of insulin aspart in paediatric subjects with type 1 diabetes
33. Patient preference for insulin lispro versus humulin R in adolescents with type 1 diabetes
34. Lispro or regular insulin for multiple injection therapy in adolescence
35. Use of insulin lispro in pregnancy
36. A reproductive and developmental toxicity study in CD rats of LY275585,{Lys(B28), Pro, (B29)}-Human Insulin
37. Retinopathy risk: What is responsible? Hormones, hyperglycaemia, or humalog?
38. Metabolic and immunological effects of insulin lispro in gestational diabetes
39. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study
40. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus
41. Comparison of bedtime insilin regimens in patients with type 2 diabetes mellitus: A randomised control trial
42. Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients
43. Optimal administration of lispro insulin in hyperglycaemic type 1 diabetes
44. Soluble and lente human insulin mixtures in normal man
45. Variation in 125 I-insulin absorption and blood glucose conception
46. Inadequate suspension of neutral protamine Hagedorn (NPH) insulin in pens
47. Study of porcine and human (NPH) insulins in normal subjects
48. Effectiveness of human Ultralente versus NPH insulin in providing basal insulin replacement for an insulin Lispro multiple daily injection regimen
49. Optimal Provision of daytime NPH insulin in patients using the insulin analog Lispro
50. Optimization of evening insulin analogue lispro
51. Recombinant human insulin analogues: Recommendations for optional use
52. Comparison of postprandial versus interprandial blood glucose to HbA1c in type 1 diabetes on physiologic intensive therapy with lispro insulin at mealtime
53. Engineering novel, prolonged acting insulins
54. Novo/Sol Basal: Pharmacokinetics of a novel soluble long-acting soluble insulin analogue
55. 125I-Labeled insulin glargine (HOE901) in healthy men - Comparison with NPH insulin and the influence of different subcutaneous injection sites
56. Pharmacokinetics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, ultralente human insulin, and continuous subcutaneous infusion of insulin lispro
57. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo
58. An assessment of the variability in the pharmacodynamics (glucose lowering effect) of HOE901 compared to NPH and ultralente human insulins using euglycaemic clamp technique
59. Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes
60. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 Diabetes
61. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens
62. A 16-week comparison of the novel insulin analog insulin glargine (HOE901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes
63. Nocturnal glucose control and free insulin levels in children with type 1 diabetes by use of the long-acting HOE901 as part of a three-injection regimen
64. Less nocturnal hypoglycaemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes
65. Basal insulin therapy in type 2 diabetes: 28-Week comparison of insulin glargine (HOE901) and NPH insulin
66. The bio-activity of insulin analogues from in-vitro receptor binding to in-vivo glucose uptake
67. Modifications in the B10 and B26-30 regions of the B chain of human insulin after affinity for the human IGF-1 receptor more than for the insulin receptor
68. Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor
69. B32] insulin (HOE 901) in muscle cells
70. The long acting human insulin analog HOE 901: Characteristics of insulin signalling in comparison to Asp(B10) and regular insulin
71. Soluble, fatty acid acylated insulins bind to albumin and show protracted actions in pigs
72. Time-action profile of the soluble fatty acid acylated long acting insulin analogue NN304
73. Comparison of the soluble basal insulin analog insulin determir with NPH insulin: A randomised, open, cross-over trial in type 1 diabetic subjects on basal-bolus therapy
74. Effect of fatty acids and selected drugs on the albumin binding of long-acting, acylated insulin analogue
75. Demonstration of a relativity hepatoselective effect of covalent insulin dimers on glucose metabolism in dogs
76. Novel hepatoselective insulin analogues: Studies with covalently linked thyroxyl-insulin complexes
77. A new concept for long-acting insulin. Spontaneous conversion of an inactive modified insulin to the active hormone in circulation: 9-Fluorenylmethoxycarbonyl derivative of insulin
78. Reduced solubility of short-acting soluble insulins when mixed with longer-acting insulins
79. The effect of mixing human soluble and human crystalline zinc-suspension insulin: Plasma insulin and blood glucose profiles after subcutaneous injection
80. Use of premixed insulin among the elderly. Reduction of errors in patient preparation of mixtures
81. Time-action profiles of novel premixed preparations of insulin lispro and NPL insulin
82. Lispro Mix25 insulin as premeal therapy in type 2 diabetic patients
83. Improved postprandial glycemic control with Humalog Mix 75/25 after a standard test meal in patients with type 2 diabetes mellitus
84. Less nocturnal hypoglycaemia during treatment with evening administration of Humalog Mix25, a lispro/intermediate insulin mixture
85. Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart
86. Optimized basal-bolus therapy using a fixed mixture of 75% lispro and 25% NPL insulin in type 1 diabetes patients: No favorable effects on glycemic control, physiological responses to hypoglycaemia, well-being, or treatment satisfaction